反応式
[F:1][C:2]1[CH:3]=[C:4](B(O)O)[CH:5]=[CH:6][CH:7]=1.C([N:18]1[CH:22]=[CH:21][N:20]=[C:19]1[C:23]1[CH:24]=[N:25][CH:26]=[CH:27][CH:28]=1)C1C=CC=CC=1.[C:29]([C:31]1[CH:32]=[N:33][CH:34]=CC=1)#[N:30].C(N1C=CN=C1C1C=CC=CC=1)C1C=CC=CC=1>ClCCl.CO>[F:1][C:2]1[CH:3]=[C:4]([C:34]2[N:30]=[CH:29][C:31]([C:22]3[NH:18][C:19]([C:23]4[CH:24]=[N:25][CH:26]=[CH:27][CH:28]=4)=[N:20][CH:21]=3)=[CH:32][N:33]=2)[CH:5]=[CH:6][CH:7]=1参加物
実験手順
The title compound was prepared by the method described in Example 1, except that (i) commercially available 3-flourobenzene boronic acid was used instead of benzeneboronic acid in Step A, and (ii) 3-(1-benzyl-1H-imidazol-2-yl)pyridine (prepared according to the method described in Example 8, Step A, except that commercially available 3-cyanopyridine was used instead of 3-fluorobenzonitrile) was used in place of the 1-benzyl-2-phenyl-1H-imidazole in Step C; Rf 0.35 with 95:5 v/v dichloromethane-methanol; melting point 309° C; 1H-NMR (400 MHz; DMSO-d6) δ 9.40 (s, 2H), 9.27 (d,1H), 8.64 (dd, 1H), 8.40 (dt, 1H), 8.31 (dd, 1H), 8.23 (bs, 1H), 8.18-8.13 (m, 1H), 7.66-7.55 (m, 3H), 7.42 (dt, 1H); MS (ESI+) m/z 318.0 (M+1); H-PGDS FPBA IC50: 0.156 μM; H-PGDS inhibitor EIA IC50: 0.041 μM.
後処理
- customprepared
出典と根拠
- ORDレコード
- ord-f128e40879df4370bd8c9c3b2c605b79
- 出典データセット
- uspto-grants-2013_09
- 特許番号
- US08536185B2
関連ノート
読み込み中…